RxDoctor Payments DataLook up a doctor →

Kinloch Nelson, MD

Urology · Richmond, VANPI 1023205739

Payments from drug & device makers

$25,370in general payments, 2019–2025

Across 940 payments — averaging $26.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$4K
  • Dendreon Pharmaceuticals LLC$4K
  • Johnson & Johnson$3K
  • Sumitomo Pharma America, Inc.$2K
  • Astellas Pharma US Inc$2K
  • AstraZeneca$1K
  • plus $10K from 45 others

What the payments were for

  • Consulting fees$3,52214%
  • Food & beverage$21,34884%
  • Education$5002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,370 in reported general payments places this provider in the 85th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$979,693
Medicare patients
1,340
Services billed
30,741

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NubeqaDarolutamide148$2,031,391
XtandiEnzalutamide79$1,049,396
ErleadaApalutamide29$345,712
Abiraterone Acetate214$333,322
OrgovyxRelugolix79$208,220
GemtesaVibegron128$84,999
MyrbetriqMirabegron70$61,021
Tamsulosin Hcl862$12,182
Mirabegron ErMirabegron15$11,294
Tadalafil64$9,322
Methenamine Hippurate100$8,161
Dutasteride182$5,102
Solifenacin Succinate93$4,715
Silodosin47$4,246
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst70$3,857

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerNubeqa$3,988$2,031,391148 claims
Astellas Pharma US IncXtandi, Myrbetriq$1,514$1,110,417149 claims
Johnson & JohnsonErleada$3,055$345,71229 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$1,532$293,218207 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 300 urology providers in Virginia.

Other urology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →